In An Updated Analysis From Phase 3 NATALEE Trial Of Novartis' Kisqali (Ribociclib) Added To Endocrine Therapy Shows Deepening Benefit Beyond Three-year Treatment Period, Reducing Risk Of Recurrence By 28.5%, Compared To ET Alone, For Stage II And III Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Novartis' Phase 3 NATALEE trial results show that adding Kisqali (Ribociclib) to endocrine therapy significantly reduces the risk of recurrence in certain early breast cancer patients by 28.5% beyond a three-year treatment period.
September 16, 2024 | 8:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Kisqali, when added to endocrine therapy, reduces the risk of recurrence in early breast cancer patients by 28.5% beyond three years, according to Phase 3 NATALEE trial results.
The positive trial results for Kisqali suggest a significant advancement in treatment for early breast cancer, likely boosting investor confidence in Novartis' oncology portfolio and potentially driving up the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100